The DGCCRF and the Ministry of Health have warned of around thirty references to non-compliant condoms sold online and in stores, presenting health risks.
AI-generated summary
The DGCCRF and the Ministry of Health have issued an alert concerning the sale of condoms that do not meet safety standards in France.
Condoms with a slick design, sold in pharmacies or in high-end sex shops, but do not comply with regulations. The Fraud Repression Agency (DGCCRF) and the Ministry of Health launched the alert this Friday: around thirty non-compliant condom references - or 40,000 condoms - have been sold in recent months in France, both online, in pharmacies and in stores. They are likely to cause unwanted pregnancies, but also sexually transmitted infections. At the end of May and the beginning of August, nearly 260,000 condoms had already been recalled. How to check that you are not affected? We'll answer you.
Which condoms are affected?
Around a thousand boxes, or more than 40,000 non-compliant condoms, have been sold in recent months. Most of the products were sold on the Internet, via Asian distributors, specifies the joint press release from the DGCCRF and the Directorate General of Health (DGS).
The brands concerned, referenced on the Rappel Conso website, are Friday Bae (The Condom), Okamoto (003 and 002), Sagami (Sagami Original 002), and My Lubie. For the latter, the products are sold both on Amazon, but also in pharmacies and in various brands such as Nuoo, Mademoiselle Bio, Monoprix, Ayanature and Passage du Désir.
How are they not compliant?
Most of the condoms identified do not have a CE (Conformité Européenne) marking, a regulatory obligation attesting that a product meets the safety, health and environmental requirements of the European Union. They also do not have a conformity assessment by a third party organization, nor, for the most part, packaging in French.
Checks in stores and pharmacies also made it possible to identify two references of condoms having obtained the CE marking and yet non-compliant due to a “risk of bursting” for one and “the presence of perforations” for the other. Non-compliant condoms can pose serious risks to the health and safety of users: sexually transmitted infections and unwanted pregnancies.
What to do if you bought one?
The authorities recommend that consumers who have used these condoms be screened for sexually transmitted infections and take a pregnancy test if a late period is noted. When purchasing condoms, the two institutions invite consumers to check the presence of a CE marking affixed by the manufacturer, the identity and reliability of the seller, the presence of instructions for use in French which must in particular specify the precautions for use and contraindications, as well as the condition of the packaging and the expiry date.
Online platforms have been ordered to immediately remove listings for the affected products and inform buyers and third-party sellers of the non-compliance of the condoms. In total, 36 ads were removed immediately. Resellers have undertaken to examine their verification systems and filtering rules on these products.
AI outlook — possibilities, not facts
Removal of online listings and review of dealer verification systems.
Very likely · Within days

La DGCCRF a alerté sur le rappel d'environ 40 000 préservatifs défectueux vendus en ligne et en pharmacie. Ces produits présentent des risques de rupture ou de perforations, pouvant entraîner des grossesses non désirées ou des infections sexuellement transmissibles.
Les vagues de chaleur en Europe ont causé plus de 30.000 décès excédentaires depuis fin mai, selon EuroMomo. L'Allemagne, la France et l'Espagne enregistrent les bilans les plus lourds, touchant particulièrement les personnes âgées de 75 ans et plus.

La Répression des fraudes et le ministère de la Santé alertent sur une trentaine de références de préservatifs non conformes vendus en ligne et en pharmacie, présentant des risques d'IST et de grossesses non désirées.

L'Assurance-maladie a mis à jour sa documentation sur l'encéphalomyélite myalgique, reconnaissant cette pathologie comme une maladie physique invalidante et non psychologique, une avancée saluée par les associations de patients.
Face aux critiques, le gouvernement français renonce au doublement immédiat du plafond annuel des franchises médicales et opte pour une indexation sur l'inflation depuis 2005, selon la ministre de la Santé Stéphanie Rist.

Moderna et Merck ont testé avec succès une thérapie combinant immunothérapie et vaccin personnalisé contre les rechutes de mélanome, réduisant significativement le risque de récidive chez plus de 1100 patients suivis.